BACKGROUND AND OBJECTIVE: Photodynamic therapy (PDT) is a local antineoplastic treatment with the potential for tumor cell specificity. PDT using either hematoporphyrin derivatives or 5-aminolevulinic acid (ALA) has been reported to induce brain edema indicating disruption of the blood-brain barrier (BBB). We have evaluated the ability of ALA-mediated PDT to open the BBB in rats. This will permit access of chemotherapeutic agents to brain tumor cells remaining in the resection cavity wall, but limit their penetration into normal brain remote from the site of illumination. STUDY DESIGN/ MATERIALS AND METHODS: ALA-PDT was performed on non-tumor bearing inbred Fischer rats at increasing fluence levels. Contrast T(1)-weighted high field (3 T) magnetic resonance imaging (MRI) scans were used to monitor the degree of BBB disruption which could be inferred from the intensity and volume of the contrast agent visualized. RESULTS: PDT at increasing fluence levels between 9 and 26 J demonstrated an increasing contrast flow rate. A similar increased contrast volume was observed with increasing fluence rates. The BBB was found to be disrupted 2 hours following PDT and 80-100% restored 72 hours later at the lowest fluence level. No effect on the BBB was observed if 26 J of light was given in the absence of ALA. CONCLUSION: ALA-PDT was highly effective in opening the BBB in a localized region of the brain. The degradation of the BBB was temporary in nature at fluence levels of 9 J, opening rapidly following treatment and significantly restored during the next 72 hours. No signs of tissue damage were seen on histological sections at this fluence level. However, higher fluences did demonstrate permanent tissue changes localized in the immediate vicinity of the light source. (c) 2008 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVE: Photodynamic therapy (PDT) is a local antineoplastic treatment with the potential for tumor cell specificity. PDT using either hematoporphyrin derivatives or 5-aminolevulinic acid (ALA) has been reported to induce brain edema indicating disruption of the blood-brain barrier (BBB). We have evaluated the ability of ALA-mediated PDT to open the BBB in rats. This will permit access of chemotherapeutic agents to brain tumor cells remaining in the resection cavity wall, but limit their penetration into normal brain remote from the site of illumination. STUDY DESIGN/ MATERIALS AND METHODS:ALA-PDT was performed on non-tumor bearing inbred Fischer rats at increasing fluence levels. Contrast T(1)-weighted high field (3 T) magnetic resonance imaging (MRI) scans were used to monitor the degree of BBB disruption which could be inferred from the intensity and volume of the contrast agent visualized. RESULTS: PDT at increasing fluence levels between 9 and 26 J demonstrated an increasing contrast flow rate. A similar increased contrast volume was observed with increasing fluence rates. The BBB was found to be disrupted 2 hours following PDT and 80-100% restored 72 hours later at the lowest fluence level. No effect on the BBB was observed if 26 J of light was given in the absence of ALA. CONCLUSION:ALA-PDT was highly effective in opening the BBB in a localized region of the brain. The degradation of the BBB was temporary in nature at fluence levels of 9 J, opening rapidly following treatment and significantly restored during the next 72 hours. No signs of tissue damage were seen on histological sections at this fluence level. However, higher fluences did demonstrate permanent tissue changes localized in the immediate vicinity of the light source. (c) 2008 Wiley-Liss, Inc.
Authors: H Christopher Lawson; Prakash Sampath; Eileen Bohan; Michael C Park; Namath Hussain; Alessandro Olivi; Jon Weingart; Lawrence Kleinberg; Henry Brem Journal: J Neurooncol Date: 2006-12-14 Impact factor: 4.130
Authors: N D Doolittle; M E Miner; W A Hall; T Siegal; E Jerome; E Osztie; L D McAllister; J S Bubalo; D F Kraemer; D Fortin; R Nixon; L L Muldoon; E A Neuwelt Journal: Cancer Date: 2000-02-01 Impact factor: 6.860
Authors: Henry Hirschberg; Dag R Sørensen; Even Angell-Petersen; Qian Peng; Bruce Tromberg; Chung-Ho Sun; Signe Spetalen; Steen Madsen Journal: J Environ Pathol Toxicol Oncol Date: 2006 Impact factor: 3.567
Authors: John H Sampson; Gamal Akabani; Gary E Archer; Darell D Bigner; Mitchel S Berger; Allan H Friedman; Henry S Friedman; James E Herndon; Sandeep Kunwar; Steve Marcus; Roger E McLendon; Alison Paolino; Kara Penne; James Provenzale; Jennifer Quinn; David A Reardon; Jeremy Rich; Timothy Stenzel; Sandra Tourt-Uhlig; Carol Wikstrand; Terence Wong; Roger Williams; Fan Yuan; Michael R Zalutsky; Ira Pastan Journal: J Neurooncol Date: 2003-10 Impact factor: 4.130
Authors: Marlon S Mathews; David Chighvinadze; H Michael Gach; Francisco A Uzal; Steen J Madsen; Henry Hirschberg Journal: Lasers Surg Med Date: 2011-11 Impact factor: 4.025
Authors: Tiara S Napier; Neha Udayakumar; Aditi H Jani; Yolanda E Hartman; Hailey A Houson; Lindsay Moore; Hope M Amm; Nynke S van den Berg; Anna G Sorace; Jason M Warram Journal: Mol Cancer Ther Date: 2020-06-30 Impact factor: 6.261
Authors: Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab Journal: CA Cancer J Clin Date: 2011-05-26 Impact factor: 508.702
Authors: Jonathan M Fahey; Joseph V Emmer; Witold Korytowski; Neil Hogg; Albert W Girotti Journal: Photochem Photobiol Date: 2016-10-17 Impact factor: 3.421
Authors: Henry Hirschberg; Michelle J Zhang; H Michael Gach; Francisco A Uzal; Qian Peng; Chung-Ho Sun; David Chighvinadze; Steen J Madsen Journal: J Neurooncol Date: 2009-06-09 Impact factor: 4.130
Authors: Steen J Madsen; H Michael Gach; Seok Jin Hong; Francisco A Uzal; Qian Peng; Henry Hirschberg Journal: Lasers Surg Med Date: 2013-08-30 Impact factor: 4.025